L., Ingwersen, S
The Study at a Glance Who was studied: 132 children and adolescents aged 1017 with type 2 diabetes Duration: 52 weeks (with the primary endpoint measured at week 26) Design: Randomized, double-blind, placebo-controlled Drug: Oral semaglutide at once-daily doses of 3 mg, 7 mg, or 14 mg Background therapy: Participants continued on metformin, basal insulin, or both The Results The trial met its primary endpoint
Semaglutide reduces inflammation markers in the body, offering additional protection for the kidneys
The inflammation may begin when bacteria or stool are caught in the diverticula
The results were published Wednesday in the journal JAMA Psychiatry
[DOI] [PMC free article] [PubMed] [Google Scholar] 1606.Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH